Podcast Episodes

Our patients, families, and caregivers have been asking us for more ways to learn about rare blood cancers and bone marrow failure diseases. So, we're coming to you today, thanks to generous support from individual donors and our corporate partners.

Dr. Eunice Wang discusses Secondary MDS

Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.

Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator

Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator. Dr. Steensma is an associate professor at Harvard Medical School and faculty member in the leukemia program at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts and the Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute

AAMDSIF Podcast for Patients: Dr. Yacoub explains MDS/MPN Overlap Diagnosis and Treatment

Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.

AAMDSIF Podcast for Patients: Dr. Amit Verma discusses approval of Luspatercept for certain MDS patients

Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.

#MDS #treatingMDS

AAMDSIF Podcast for Patients: Dr. Gustavo Rivero discusses Low-Risk MDS

Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.

Dr. Vu Duong explains High-Risk and Low-Risk MDS

Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.

MDS to AML, treatment and options with Dr. Tiffany Tanaka, UC San Diego

Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.

Eliot thrives after transplant and clinical trial for MDS - AML

Eliot's disease of Myelodysplastic Syndromes with IDH1 and IDH2 mutations developed quickly. His son was his donor for the haploidentical bone marrow transplant, and now he thrives thanks to a clinical trial drug that keeps the Acute Myeloid Leukemia and MDS in remission. Listen to his story now.